Provided by Tiger Trade Technology Pte. Ltd.

Biomarin Pharmaceutical

65.58
+0.06500.10%
Volume:65.55K
Turnover:4.30M
Market Cap:12.67B
PE:173.03
High:66.00
Open:65.96
Low:65.29
Close:65.51
52wk High:70.98
52wk Low:49.26
Shares:193.27M
Float Shares:192.12M
Volume Ratio:0.43
T/O Rate:0.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3790
EPS(LYR):1.80
ROE:1.18%
ROA:3.26%
PB:2.00
PE(LYR):36.43

Loading ...

BioMarin to host first-quarter results conference call and webcast

Reuters
·
Apr 27

Morgan Stanley Resumes BioMarin Pharmaceutical at Overweight With $120 Price Target

MT Newswires Live
·
Apr 27

BioMarin resumed with an Overweight at Morgan Stanley

TIPRANKS
·
Apr 27

Piper Sandler Sticks to Their Buy Rating for BioMarin Pharmaceutical (BMRN)

TIPRANKS
·
Apr 24

BioMarin wins French FDI clearance for Amicus merger, closing expected April 27

Reuters
·
Apr 24

Biomarin Pharmaceutical Inc - France Grants Fdi Clearance for Biomarin-Amicus Merger on April 23, 2026 - SEC Filing

THOMSON REUTERS
·
Apr 24

BioMarin’s BMN 333 Takes On Vosoritide in High Stakes Achondroplasia Trial

TIPRANKS
·
Apr 24

BRIEF-Biomarin Announces Board Leadership Transition

Reuters
·
Apr 22

Biomarin Pharmaceutical Inc - Richard a. Meier to Retire From Board After Annual Meeting

THOMSON REUTERS
·
Apr 22

Press Release: BioMarin Announces Board Leadership Transition

Dow Jones
·
Apr 22

Is It Time To Reassess BioMarin Pharmaceutical (BMRN) After A 42.7% Three-Year Share Price Fall

Simply Wall St.
·
Apr 10

RBC Capital Sticks to Their Hold Rating for BioMarin Pharmaceutical (BMRN)

TIPRANKS
·
Apr 09

BioMarin Pharmaceutical Secures European Regulatory Approval for Amicus Therapeutics Acquisition

MT Newswires Live
·
Apr 07

What BioMarin Pharmaceutical (BMRN)'s Voxzogo Trial Stops and Mixed Safety Data Mean For Shareholders

Simply Wall St.
·
Mar 31

Exploring High Growth Tech Stocks In The US Market March 2026

Simply Wall St.
·
Mar 27

Wells Fargo says buy BioMarin shares amid Phase 2 trial discontinuation weakness

TIPRANKS
·
Mar 17

BioMarin halts Phase 2 VOXZOGO dosing and enrollment in Turner syndrome, SHOX-deficiency and ACAN-deficiency trials

Reuters
·
Mar 16

Biomarin: Decision to Discontinue Following Occurrence of Several Slipped Capital Femoral Epiphysis Events in 2 Ongoing Investigator-Sponsored Trials

THOMSON REUTERS
·
Mar 16

Biomarin Pharmaceutical - Phase 2 Canopy Trials of Voxzogo in Noonan Syndrome, Idiopathic Short Stature to Continue - SEC Filing

THOMSON REUTERS
·
Mar 16